Propofol attenuates human proximal renal tubular epithelial cell injury induced by anoxia-reoxygenation

Laboratory Medicine

Volumn 39, Issue 6, 2008, Pages 356-360

  Feng, Yani ^a   Bai, Tao ^a   Ma, Hong ^a   Wang, Jun Ke ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 59849118962     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/YVAD9JBUFGVGAAVP     Document Type: Article

References (30)

1. Aronson S, Blumenthal R. Perioperative renal dysfunction and cardiovascular anesthesia: Concerns and controversies. J Cardiothorac Vasc Anesth. 1998;17:117-130.
2. Star RA. Treatment of acute renal failure. Kidney Int. 1998;54:1817-1831.
3. Cruz JP, Sedeno G, Carmona JA, et al. The in vitro effects of propofol on tissular oxidative stress in the rat. Anesth Analg. 1988;87:1141-1146.
4. Murphy PG, Myers DS, Davies MJ, er al. The antioxidant potential of propofol (2,6-diisopropylphenol). Br J Anaesth. 1992;68:613-618.
5. Mathy-Hartert M, Mouithys-Mickalad A, Kohnen S, et al. Effects of propofol on endothelial cells subjected to a peroxynitrite donor (SIN-1). Anaesthesia. 2000;55:1066-1071.
6. Vasant G, Trauger RJ, Cameron A, et al. Propofol hemisuccinate suppression of experimental autoimmune encephalomyelitis. Autoimmunity. 2007;40:180-186.
7. Fujinaga A, Fukushima Y, Kojima A, et al. Anesthetic management of an extremely obese patient. J Anesth. 2007;21:261-264.
8. Bovill JG. Intravenous anesthesia for the patient with left ventricular dysfunction. Semin Cardiothorac Vasc Anesth. 2006;10:43-48.
9. Runzer TD, Ansley DM, Godin DV, et al. Tissue antioxidant capacity during anesthesia: Propofol enhances in vivo red cell and tissue antioxidant capacity in a rat model. Anesth Analg. 2002;94:89-93.
10. Rodriguez-Lopez JM, Sanchez-Conde P, Lozano FS, et al. Laboratory investigation: Effects of propofol on the systemic inflammatory response during aortic surgery. Can J Anaesth. 2006;53:701-710.
11. Croinin DF, Shorten DG. Anesthesia and renal disease. Curr Opin Anaesthesiol. 2002;15:359-363.
12. Chatterjee PK, Thiemermann C. Emerging drugs for renal failure. Expert Opin Emerg Drugs. 2003;8:389-435.
13. Park KM, Chen A, Bonventre JV. Prevention of kidney ischemia/ reperfusion-induced functional injury and JNK, p38, and MAPK kinase activation by remote is chemic pretreatment. J Biol Chem. 2001;276:11870-11876.
14. Wang J, Huang H, Liu P, et al. Inhibition of phosphorylation of p38MAPK involved in the protection of nephropathy by emodin in diabetic rats. Eur J Pharmacol. 2006;553:297-303.
15. Cuttle L, Zhang X, Endre Z. Bcl-X translocation in renal tubular epithelial cells in vitro protects distal cells from oxidative stress. Kidney Int. 2001;59:1779-1788.
16. Thomas L, Ota-setlik A, Fu Y, et al. Differential protection effects of volatile anesthetics against renal ischemia-reperfusion injury in vivo. Anesthesiology. 2004;101:1313-1324.
17. Susan V, Mclennan DK, Yue, et al. Effect of glucose on matrix metalloproteinase activity in mesangial cells. Nephron. 1998,89:293-298.
18. White PF. Propofol. In: White PF, ed. Textbook of Intravenous Anesthesia. Baltimore, MD: Williams and Wilkins; 1997: 111-152.
19. Kazuo Yamabe, Shigeomi Shimizu, Wataru Kamiike, et al. Prevention of hypoxic liver cell necrosis by in vivo human Bcl-2 gene transfection. Biochem Biophys Res Commun. 1998;1:217.
20. Ypsilantis P, Politou M, Mikroulis D, et al. Organ toxicity and mortality in propofol-sedated rabbits under prolonged mechanical ventilation. Anesth Analg. 2007;105:155-166.
21. Kam PC, Cardone D. Propofol infusion syndrome. Anaesthesia. 2007;62:690-701.
22. Bennett BG. In: Environmental Nickel Pathways to Man, International Agency for Research on Cancer (IARC) Scientific Publication. Lyon, France: IARC; 53: 487-495.
23. Maxwell P, Salnikow K. HIF-1: An oxygen and metal responsive transcription factor. Cancer Biol Ther. 2004;3:29-35.
24. Salnikow K, Donald SP, Bruick RK, et al. Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress. J Biol Chem. 2004:279:40337-40344.
25. Li R, Ding T, Liu X, et al. Influence of SB203580 on cell apoptosis and P38MAPK in renal ischemia/reperfusion injury. J Huazhong Univ Sci Thchnolog Med Sci. 2006;26:50-52.
26. Armstrong SC, Delacey M, Ganote CE, et al. Phosphorylation state of hsp27 and p38MAPK during preconditioning and protein phosphatase inhibitor protection of rabbit cardiomyocytes. J Mol Cell Cardiol. 1999;31:55-67.
27. Park KM, Chen A, Bonventre JV. Prevention of kidney ischemia/ reperfusion-induced functional injury and JNK, p38, and MAPK kinase activation by remote ischemic pretreatment. J Biol Chem. 2001;276:11870-11876.
28. Oberbauer R, Schwar C. Regulation of renal tubular cell apoptosis and proferation after ischemia injury to solitary kidney. J Lab Clin Med. 2001;138:343-351.
29. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: Release of cytochrome C from mitochondria blocked. Science. 1997;275:1129-1132.
30. Hatip A, Khatib I, Iwasaki K, et al. Inhibition of poly (ADP2ribose) polymerase and caspase-3, but not caspase-1, prevents apoptosis and improves spatial memory of rats with twice-repeated cerebra ischemia. Life Sci. 2004; 75:1967-1978.